• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

cstam@unimelb.edu.au

Credentials


Position
Clinical (Professor)
Department of Medicine
Education
Doctorate (Research)
University of Melbourne
Bachelors Degree (Honours)
University of Melbourne
ORCID

0000-0002-9759-5017

Prof Constantine Tam

Clinical (Professor)
Department of Medicine

907 Scholarly works
7 Projects

HIGHLIGHTS

  • 2022

    Journal article

    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
    DOI: 10.1182/blood.2022016040
  • 2022

    Journal article

    Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
    DOI: 10.1182/bloodadvances.2022008325
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2022

    Journal article

    Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
    DOI: 10.1182/bloodadvances.2021005621
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Understanding and Averting Blood Cancer Resistance to Therapy
  • 2019

    Research grants (ARC, NHMRC, MRFF)

    The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
  • 2017

    Research Grant

    Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
Constantine Tam

Latest Honours,
Awards and Fellowships


2013
Herman Clinical Fellow of Cancer Research University of Melbourne
2010
Teaching Excellence Award University of Melbourne
2009
Clinical Investigator Fellowship Sylvia and Charles Viertel Foundation
2008
Merit Award American Society of Clinical Oncology

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    First-line treatment for CLL in the era of targeted therapy
    DOI: 10.1038/s41408-025-01434-2
  • 2026

    Journal article

    An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL
    DOI: 10.1182/bloodadvances.2025018536
  • 2026

    Journal article

    Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies
    DOI: 10.1016/j.esmoop.2026.106086
  • 2026

    Journal article

    Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell Therapy
    DOI: 10.1016/j.jtct.2025.11.031
  • 2026

    Journal article

    Cognitive Recovery Following Immune Effector Cell-Associated Neurotoxicity Syndrome in the First 6 Months after Chimeric Antigen Receptor T-Cell Therapy.
    DOI: 10.1016/j.jtct.2026.03.030
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study
    DOI: 10.3324/haematol.2025.287919
  • 2026

    Journal article

    The APLC expert consensus recommendations on the management of chronic lymphocytic leukaemia in Asia
    DOI: 10.47102/annals-acadmedsg.2025410

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224